Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma

References

• BARRET, A. J. and STARKEY, P. M., 1973, The interaction of a2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochemical Journal, 133, 709–724.
   PubMed Web of Science ®Google Scholar
• BUESSECKER, F., BEINARTZ, J., SCHIRMER, U. and KRAMER, M. D., 1993, Enzyme-linked immunosorbent assays for plasminogen activator. Journal of Immunological Methods, 162, 193–200.
   PubMedGoogle Scholar
• CoLucci, M., BARAMA, J. A. and COTTEN, D., 1985, Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. Journal of Clinical Investigation, 75, 818–824.
   PubMed Web of Science ®Google Scholar
• HAGGROTH, L., MATTSSON, C. and FRIBERG, J., 1984, Inhibition of the human tissue plasminogen activator in plasma from different species. Thrombosis Research, 33, 583–594.
   PubMedGoogle Scholar
• HOLVOET, P., CLEEMPUT, H. and COLLEN, D., 1985, Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thrombosis and Haemostasis, 54, 684–687.
   PubMedGoogle Scholar
• HUBER, K., BECKMANN, R., LANG, I., SCHUSTER, E. and BINDER, B. R., 1989, Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity. Fibrinolysis, 3, 41–43.
   Google Scholar
• IIDA, S., IwAmoTo, M., Suzum, M. and KOMATSU, T., 1988, Metabolic fate of recombinant human tissue plasminogen activator (rt-PA) (1). Xenobiotk Metabolism and Disposition, 3, 309–329.
   Google Scholar
• KATOH, M., SUZUKI, Y., MIYAMOTO, I. and WATANABE, T., 1991, Biochemical and pharmacokinetics properties of pamiteplase, a novel fibrinolytic agent. Thrombosis and Haemostasis, 65, 1193.
   Google Scholar
• KAWASAKI, T., KAWAMURA, S., KATOH, S. and TAKENAKA, T., 1993a, Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. Japanese Journal Pharmacology, 63, 135–142.
   PubMedGoogle Scholar
• KAWASAKI, T., KATOH, M., KAKU, S., GUSHIMA, H., TAKENAKA, T., Yui, Y. and KAWAI C., 1993b, Thrombolytic activity of a novel modified tissue-type plasminogen activator, Y1V1866, in a canine model of coronary artery thrombosis. Japanese Journal Pharmacology, 63, 9–16.
   Google Scholar
• KAWASAKI, T., KATOH, M., KAKU, S., GUSHIMA, H., TAKENAKA, T., Yu', Y. and KAWAI C., 1993c, Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis. Japanex Journal Pharmacology, 63, 319–325.
   Google Scholar
• KAWAUCHI, Y., MORINAGA, T., YOKOTA, M., KINOSHITA, A., KAWAMURA, K., SUZUKI, Y., TAKAYAMA, M., FURUICHI, K. and GUSHIMA, H., 1991, Gene construction and large scale production of a novel fibrinolytic agent (pamiteplase) in CHO cells. Thrombosis and Haemostasis, 65, 1193.
   Google Scholar
• KERINS, D. M., ROY, L., KUNITADA, S., ADEDOYIN, A., FITZGERALD, G. A. and FITZGERALD, D. J., 1992, Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Circulation, 85, 526–532.
   PubMedGoogle Scholar
• KOMURO, S., YAMAMOTO, R., ITou, M., IBA, I., YOSHITAKE, A., SAKURAMA, T. and KANEKO, M., 1989, Metabolic fate of SM-9527 in rats. Clinical report, 23, 115–132.
   Google Scholar
• KORNINGER, C. and COLLEN, D., 1981, Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: No evidence for a specific inhibitor. Thrombosis and Haemostasis, 46, 662–665.
   PubMedGoogle Scholar
• MOROI, M. and Aom, N., 1976, Isolation and characterization of arplasmin inhibitor from human plasma. Journal of Biochemical Chemistry, 251, 5956–5965.
   Google Scholar
• OIKAWA, K., KAMIMURA, H., WATANABE, T., HIGUCHI, S. and MIYAMOTO I., 1996a, Pharmacokinetics of Y1V1866 and t-PA after intravenous administration to rats and dogs. Clinical Pharmacology and Therapy, 6, 2391–2396.
   Google Scholar
• OIKAWA, K., KAMIMURA, H., WATANABE, T., MIYAMOTO, I. and HIGUCHI, S., 1996b, Metabolic fate of Y1V1866, a novel fibrinolytic agent. Xenobiotk Metabolism and Disposition, 11, 1–10.
   Google Scholar
• OKUMURA, I., AOKI, S., OHNO, T., IBA, Y., NISHIMOTO, K. and BABA, S., 1989, Metabolic fate of TD-2061(I). Progress Medicine, 9,483–503.
   Google Scholar
• SCHRAUWEN, Y., EATEis, J. J. and KOOISTRA, T., 1994, A sensitive ELISA for human tissue-type plasminogen activator applicable to the study of acute release from cultured human endothelial cells. Thrombosis and Haemostasis, 71, 225.
   PubMedGoogle Scholar
• SEIFRIED, E., TANSWELL, P., RIJKEN, D. C., BARRETT-BERGSHOEFF, M. M., SU, C. A. P. F. and KLUFT, C., 1988, Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittel -Forschungl Drug Research, 38,418–422.
   Google Scholar
• TAHARA, C., KAZAMA, M., MIYAJIMA, Y. and ABE, T., 1989, Circadian fluctuation of plasmatic plasminogen activator and its inhibitor PAI-1 of Japanese adults. Blood and Vessel, 20, 67–69.
   Google Scholar
• TANS WELL, P., SEIFRIED, E., Su, P. C. A. F., FEUERER, W. and RIJKEN, D. C., 1989, Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clinical Phar-macology and Therapeutics, 46, 155–162.
   Google Scholar
• VERHEIJEN, J. H., MULLAART, E., CHANG, G. T. G., KLUFT, C. and WIJNGAARDS, G., 1982, A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thrombosis and Haemostasis, 48, 266–269.
   Google Scholar
• WALTON, P. L., 1966, An improved fibrin plate method for the assay of plasminogen. Clinka et Chimka Acta, 13, 680–684.
   PubMedGoogle Scholar
• WATANABE, S., SASAMATA, M. and KATOH, M., 1989, t-PA activity assay method in blood sample using dipstick coated with a monoclonal antibody SP-322. Thrombosis and Haemostasis, 62, 95.
   Google Scholar